OQL036 / OnQuality Pharma - LARVOL DELTA

"#OnQuality Announces #FDA Clearance of #IND Application for #OQL036 for the Prophylaxis of #Capecitabine Induced Hand-Foot Syndrome https://t.co/0bUJ4g6M3D" (@1stOncology)

FDA event • Dermatology

OQL036 topical gel inhibits the skin toxicity associated with 5-fluorouracil/capecitabine: results from in vitro and in vivo preclinical studies (AACR-NCI-EORTC 2022) - "In vitro studies showed both TdR and dTNAP are effective at reducing the 5FU-induced toxicity in HaCaT cells. In animal studies, daily topical application of the prodrug gel, OQL036, releasing thymidine and naproxen delayed the onset of HFS and was effective in reducing the severity of CAP-induced HFS."

Adverse events • Preclinical • Oncology